Oppenheimer Upgrades Blackstone to Outperform Amid Market Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Source: seekingalpha
- Rating Upgrade: Oppenheimer upgraded Blackstone (BX) from Perform to Outperform, highlighting the stock's recent struggles despite its outstanding performance, particularly in real estate, indicating a market underestimation of its potential.
- Price Recovery: Blackstone (BX) shares rose 1.5% in early trading on Monday, reflecting investor confidence in its future performance, especially given its strong fundamentals in real estate and private credit, which may attract more capital inflows.
- Unique Business Model: Analysts noted that Blackstone's capital-light business model allows nearly all earnings to be returned to shareholders, with no direct controlling ownership of an insurance affiliate or significant large balance sheet investments, enhancing its appeal to investors seeking stable returns.
- Market Opportunity: Oppenheimer believes the current market dislocation presents investors with a chance to buy the industry's premier franchise at a very attractive valuation, particularly as the strong performance of its real estate business suggests significant upside in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BX
Wall Street analysts forecast BX stock price to rise
12 Analyst Rating
5 Buy
7 Hold
0 Sell
Moderate Buy
Current: 118.000
Low
166.00
Averages
176.60
High
205.00
Current: 118.000
Low
166.00
Averages
176.60
High
205.00
About BX
Blackstone Inc. is an alternative asset manager. Its asset management includes global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries, and hedge funds. Its Real Estate segment comprises its management of opportunistic real estate funds, Core+ real estate funds, and real estate debt strategies. Its Private Equity segment includes its management of flagship Corporate Private Equity funds, sector and geographically focused Corporate Private Equity funds, core private equity funds, an investment platform, and others. Its Credit & Insurance segment consists of Blackstone Credit & Insurance, which is organized into three overarching strategies: private corporate credit, liquid corporate credit and infrastructure and asset-based credit. Its Multi-Asset Investing segment is organized into four investment platforms: Absolute Return, Multi-Strategy, Total Portfolio Management, and Public Real Assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entrata Files for IPO Amid Strong Market Recovery
- IPO Filing: Entrata filed for an initial public offering (IPO) with the SEC on Thursday, marking a significant step in its capital market journey and is expected to attract considerable investor interest.
- Market Resilience: Despite ongoing geopolitical conflicts, several large IPOs have been successfully priced in the past two months, demonstrating the resilience of the U.S. IPO market and providing a favorable backdrop for Entrata's listing.
- Funding Background: In 2025, Entrata secured a $200 million minority investment from Blackstone at a valuation of $4.3 billion, establishing a solid financial foundation for its IPO and boosting investor confidence.
- Underwriter Lineup: Prestigious investment banks such as Goldman Sachs, J.P. Morgan, and Barclays will serve as underwriters for the IPO, enhancing Entrata's credibility and attractiveness in the market.
See More
EQT Partners with Google Cloud to Accelerate AI Adoption
- Access to AI Tools: EQT's partnership with Google Cloud enables over 300 portfolio companies to access AI tools, including the Gemini Enterprise Agent platform, facilitating AI adoption across sectors like enterprise software and healthcare, thereby enhancing operational efficiency and market competitiveness.
- Engineer Support: EQT's AI transformation team of approximately 85 members will collaborate with Google engineers to ensure effective deployment and customization of AI technologies, addressing the surging market demand and further bolstering the companies' competitiveness in an AI-driven economy.
- Network Expansion: EQT and its portfolio companies will gain access to Google Cloud's partner network, which includes over 330,000 specialists from consultancies like Accenture, Deloitte, and KPMG, enhancing their technical support capabilities and promoting the implementation of AI solutions.
- Increased Market Opportunities: This collaboration allows EQT's portfolio companies to sell their products on Google Cloud's online store, creating competitive dynamics with other private equity firms like Blackstone and TPG, thereby expanding market opportunities.
See More
Buffett's Succession Sparks New Strategy at Berkshire Hathaway
- Leadership Transition: Warren Buffett stepped down as CEO of Berkshire Hathaway in December 2025, handing over to Greg Abel, who previously served as vice chairman of non-insurance operations, which is expected to drive strategic transformation and enhance market competitiveness.
- Portfolio Adjustment: Abel has tripled the company's stake in Alphabet to nearly 7%, indicating a significant increase in investment within its $332 billion portfolio, which could yield substantial returns for the company.
- AI Chip Market Strategy: Alphabet has been developing TPU chips since 2015 and recently launched its 8th generation TPUs, which are expected to attract demand from AI companies, particularly through partnerships with Anthropic and Meta, potentially generating tens of billions in revenue for Alphabet.
- Strong Financial Performance: Alphabet reported a 22% year-over-year revenue increase to $109.8 billion in Q1, with operating income soaring 39% to $39.6 billion, reflecting margin expansion in its cloud computing segment, and analysts expect a 16% annual growth over the next three years, indicating the stock is slightly undervalued.
See More
Alphabet Expands TPU Market to Compete with Nvidia
- Market Expansion Strategy: Alphabet plans to allow select customers to deploy TPUs directly in their data centers, aiming to expand its market share by meeting the demands of AI labs and capital markets firms, particularly in the context of competing with Nvidia.
- Strong Financial Performance: Alphabet reported a 22% year-over-year revenue increase to $109.8 billion in Q1, with operating income soaring 39% to $39.6 billion, indicating that strong demand for TPUs and AI models is driving profitability in its cloud computing segment.
- Future Growth Potential: Analyst Gil Luria estimates that TPUs could capture 20% of the AI accelerator market over time, which would make Alphabet's custom chip business worth $900 billion, although Nvidia is expected to remain the market leader.
- Investor Considerations: Despite Alphabet's current share price of $386, Wall Street's target price of $430 implies an 11% upside, and analysts generally view the stock as slightly undervalued, with expected annual growth of 16% over the next three years.
See More
Apogee Therapeutics Partners with Blackstone for $1.3B Financing
- Financing Collaboration: Apogee Therapeutics has entered into a strategic financing collaboration with Blackstone Life Sciences, providing up to $1.3 billion in flexible, non-dilutive capital, including $800 million in synthetic royalty funding and $500 million in senior debt, aimed at supporting the development and commercialization of its advanced drug, zumilokibart.
- Royalty Structure: Blackstone will provide up to $800 million in synthetic royalty funding in exchange for low-to-mid single-digit tiered royalties on worldwide annual sales of zumilokibart for a term of 15 years, which is expected to generate long-term revenue for the company.
- Improved Cash Flow Outlook: As a result of this financing agreement, Apogee has removed its cash runway end date guidance, and combined with its current total cash of $1.3 billion, this transaction positions the company to achieve a self-sustainable financial profile without the need for future equity financing.
- Market Reaction: Despite the significant funding support from the agreement, the market reacted negatively, with Apogee's shares falling over 27% in premarket trading, indicating investor concerns regarding the company's future prospects.
See More
Medline Prices Upsized Secondary Offering of 72.6M Shares
- Upsized Offering: Medline announced an upsized secondary offering of approximately 72.6 million Class A shares at $37 per share, indicating sustained market demand despite the company not participating in the offering, which is expected to close on May 28.
- Underwriter Option: The selling shareholders granted underwriters a 30-day option to purchase up to an additional 10.8 million shares, enhancing market liquidity and investor confidence in Medline's stock.
- Stock Performance: Medline shares closed at $37.1 on Thursday and rose 0.8% in premarket trading on Friday, reflecting a positive market reaction to the offering announcement, which may attract more investor interest.
- Key Shareholder Background: The selling shareholders include affiliates of Blackstone, Hellman & Friedman, and a wholly owned subsidiary of the Abu Dhabi Investment Authority, showcasing strong institutional confidence and support for Medline.
See More
Entrata Files for IPO Amid Strong Market Recovery
- IPO Filing: Entrata filed for an initial public offering (IPO) with the SEC on Thursday, marking a significant step in its capital market journey and is expected to attract considerable investor interest.
- Market Resilience: Despite ongoing geopolitical conflicts, several large IPOs have been successfully priced in the past two months, demonstrating the resilience of the U.S. IPO market and providing a favorable backdrop for Entrata's listing.
- Funding Background: In 2025, Entrata secured a $200 million minority investment from Blackstone at a valuation of $4.3 billion, establishing a solid financial foundation for its IPO and boosting investor confidence.
- Underwriter Lineup: Prestigious investment banks such as Goldman Sachs, J.P. Morgan, and Barclays will serve as underwriters for the IPO, enhancing Entrata's credibility and attractiveness in the market.
See More
EQT Partners with Google Cloud to Accelerate AI Adoption
- Access to AI Tools: EQT's partnership with Google Cloud enables over 300 portfolio companies to access AI tools, including the Gemini Enterprise Agent platform, facilitating AI adoption across sectors like enterprise software and healthcare, thereby enhancing operational efficiency and market competitiveness.
- Engineer Support: EQT's AI transformation team of approximately 85 members will collaborate with Google engineers to ensure effective deployment and customization of AI technologies, addressing the surging market demand and further bolstering the companies' competitiveness in an AI-driven economy.
- Network Expansion: EQT and its portfolio companies will gain access to Google Cloud's partner network, which includes over 330,000 specialists from consultancies like Accenture, Deloitte, and KPMG, enhancing their technical support capabilities and promoting the implementation of AI solutions.
- Increased Market Opportunities: This collaboration allows EQT's portfolio companies to sell their products on Google Cloud's online store, creating competitive dynamics with other private equity firms like Blackstone and TPG, thereby expanding market opportunities.
See More
Buffett's Succession Sparks New Strategy at Berkshire Hathaway
- Leadership Transition: Warren Buffett stepped down as CEO of Berkshire Hathaway in December 2025, handing over to Greg Abel, who previously served as vice chairman of non-insurance operations, which is expected to drive strategic transformation and enhance market competitiveness.
- Portfolio Adjustment: Abel has tripled the company's stake in Alphabet to nearly 7%, indicating a significant increase in investment within its $332 billion portfolio, which could yield substantial returns for the company.
- AI Chip Market Strategy: Alphabet has been developing TPU chips since 2015 and recently launched its 8th generation TPUs, which are expected to attract demand from AI companies, particularly through partnerships with Anthropic and Meta, potentially generating tens of billions in revenue for Alphabet.
- Strong Financial Performance: Alphabet reported a 22% year-over-year revenue increase to $109.8 billion in Q1, with operating income soaring 39% to $39.6 billion, reflecting margin expansion in its cloud computing segment, and analysts expect a 16% annual growth over the next three years, indicating the stock is slightly undervalued.
See More
Alphabet Expands TPU Market to Compete with Nvidia
- Market Expansion Strategy: Alphabet plans to allow select customers to deploy TPUs directly in their data centers, aiming to expand its market share by meeting the demands of AI labs and capital markets firms, particularly in the context of competing with Nvidia.
- Strong Financial Performance: Alphabet reported a 22% year-over-year revenue increase to $109.8 billion in Q1, with operating income soaring 39% to $39.6 billion, indicating that strong demand for TPUs and AI models is driving profitability in its cloud computing segment.
- Future Growth Potential: Analyst Gil Luria estimates that TPUs could capture 20% of the AI accelerator market over time, which would make Alphabet's custom chip business worth $900 billion, although Nvidia is expected to remain the market leader.
- Investor Considerations: Despite Alphabet's current share price of $386, Wall Street's target price of $430 implies an 11% upside, and analysts generally view the stock as slightly undervalued, with expected annual growth of 16% over the next three years.
See More
Apogee Therapeutics Partners with Blackstone for $1.3B Financing
- Financing Collaboration: Apogee Therapeutics has entered into a strategic financing collaboration with Blackstone Life Sciences, providing up to $1.3 billion in flexible, non-dilutive capital, including $800 million in synthetic royalty funding and $500 million in senior debt, aimed at supporting the development and commercialization of its advanced drug, zumilokibart.
- Royalty Structure: Blackstone will provide up to $800 million in synthetic royalty funding in exchange for low-to-mid single-digit tiered royalties on worldwide annual sales of zumilokibart for a term of 15 years, which is expected to generate long-term revenue for the company.
- Improved Cash Flow Outlook: As a result of this financing agreement, Apogee has removed its cash runway end date guidance, and combined with its current total cash of $1.3 billion, this transaction positions the company to achieve a self-sustainable financial profile without the need for future equity financing.
- Market Reaction: Despite the significant funding support from the agreement, the market reacted negatively, with Apogee's shares falling over 27% in premarket trading, indicating investor concerns regarding the company's future prospects.
See More
Medline Prices Upsized Secondary Offering of 72.6M Shares
- Upsized Offering: Medline announced an upsized secondary offering of approximately 72.6 million Class A shares at $37 per share, indicating sustained market demand despite the company not participating in the offering, which is expected to close on May 28.
- Underwriter Option: The selling shareholders granted underwriters a 30-day option to purchase up to an additional 10.8 million shares, enhancing market liquidity and investor confidence in Medline's stock.
- Stock Performance: Medline shares closed at $37.1 on Thursday and rose 0.8% in premarket trading on Friday, reflecting a positive market reaction to the offering announcement, which may attract more investor interest.
- Key Shareholder Background: The selling shareholders include affiliates of Blackstone, Hellman & Friedman, and a wholly owned subsidiary of the Abu Dhabi Investment Authority, showcasing strong institutional confidence and support for Medline.
See More
